Predictive Biosciences Raises $25M in Series C Round | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Predictive Biosciences today said it has completed a Series C financing round, raising $25 million.

Proceeds will be used to complete multi-center clinical trials for Predictive's CertNDx bladder cancer assay and to launch the test through the company's CLIA laboratories, it said in a statement.

CertNDx uses Predictive's Multi-Analyte Diagnostic Readout, or MADR, approach, which combines DNA and protein biomarkers into one assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.